Movement Alert｜Halozyme Therapeutics Rises 16.87% in Regular Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Raised

Market Focus08-08

On August 7, Halozyme Therapeutics surged 16.87% in regular trading, reaching $100.185 per share, with turnover of $380 million. The rally was driven by a blowout Q2 earnings report and significant full-year guidance increase.

The company reported Q2 adjusted EPS of $2.28, beating the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue came in at $481 million, surpassing the $407 million estimate by roughly 19%, up 47.7% year-over-year. Growth was primarily driven by continued royalty expansion from the ENHANZE technology platform.

Halozyme also raised full-year guidance to adjusted EPS of $8.65-$9.00 on revenue of $1.835-$1.91 billion, well above the prior outlook of $7.75-$8.25 EPS on $1.71-$1.81 billion revenue, and significantly exceeding consensus estimates of $7.94 EPS on $1.77 billion revenue.

Following the results, Leerink Partners upgraded the stock to Outperform with a target price raised from $83 to $110, while Morgan Stanley lifted its target from $93 to $105, maintaining an Overweight rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141348692?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-08 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141348692","market":"us","top_or_hot":-1,"title":"Movement Alert｜Halozyme Therapeutics Rises 16.87% in Regular Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On August 7, Halozyme Therapeutics surged 16.87% in regular trading, reaching $100.185 per share, with turnover of $380 million. The rally was driven by a blowout Q2 earnings report and significant full-year guidance increase.</p><p>The company reported Q2 adjusted EPS of $2.28, beating the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue came in at $481 million, surpassing the $407 million estimate by roughly 19%, up 47.7% year-over-year. Growth was primarily driven by continued royalty expansion from the ENHANZE technology platform.</p><p>Halozyme also raised full-year guidance to adjusted EPS of $8.65-$9.00 on revenue of $1.835-$1.91 billion, well above the prior outlook of $7.75-$8.25 EPS on $1.71-$1.81 billion revenue, and significantly exceeding consensus estimates of $7.94 EPS on $1.77 billion revenue.</p><p>Following the results, Leerink Partners upgraded the stock to Outperform with a target price raised from $83 to $110, while Morgan Stanley lifted its target from $93 to $105, maintaining an Overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Halozyme Therapeutics Rises 16.87% in Regular Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Halozyme Therapeutics Rises 16.87% in Regular Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-08 00:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, Halozyme Therapeutics surged 16.87% in regular trading, reaching $100.185 per share, with turnover of $380 million. The rally was driven by a blowout Q2 earnings report and significant full-year guidance increase.</p><p>The company reported Q2 adjusted EPS of $2.28, beating the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue came in at $481 million, surpassing the $407 million estimate by roughly 19%, up 47.7% year-over-year. Growth was primarily driven by continued royalty expansion from the ENHANZE technology platform.</p><p>Halozyme also raised full-year guidance to adjusted EPS of $8.65-$9.00 on revenue of $1.835-$1.91 billion, well above the prior outlook of $7.75-$8.25 EPS on $1.71-$1.81 billion revenue, and significantly exceeding consensus estimates of $7.94 EPS on $1.77 billion revenue.</p><p>Following the results, Leerink Partners upgraded the stock to Outperform with a target price raised from $83 to $110, while Morgan Stanley lifted its target from $93 to $105, maintaining an Overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"","article_id":"1141348692","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141348692","pubTimestamp":1786119330,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, Halozyme Therapeutics surged 16.87% in regular trading, reaching $100.185 per share, with turnover of $380 million. The rally was driven by a blowout Q2 earnings report and significant...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗"},"translate_title":"走势提醒|Halozyme Therapeutics 常规交易上涨 16.87%，第二季度盈利大幅超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"On August 7, Halozyme Therapeutics surged 16.87% in regular trading, reaching $100.185 per share, with turnover of $380 million. The rally was driven by a blowout Q2 earnings report and significant full-year guidance increase.The company reported Q2 adjusted EPS of $2.28, beating the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue came in at $481 million, surpassing the $407 million estimate by roughly 19%, up 47.7% year-over-year. Growth was primarily driven by continued royalty expansion from the ENHANZE technology platform.Halozyme also raised full-year guidance to adjusted EPS of $8.65-$9.00 on revenue of $1.835-$1.91 billion, well above the prior outlook of $7.75-$8.25 EPS on $1.71-$1.81 billion revenue, and significantly exceeding consensus estimates of $7.94 EPS on $1.77 billion revenue.Following the results, Leerink Partners upgraded the stock to Outperform with a target price raised from $83 to $110, while Morgan Stanley lifted its target from $93 to $105, maintaining an Overweight rating.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141348692","isCrawlerRequest":true}